Topics

Plexxikon Inc. Company Profile

17:14 EST 24th January 2020 | BioPortfolio

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment of diabetes, and PLX3397 for the treatment of metastatic cancer. Among the company’s preclinical programs, candidates are being developed for the treatment of neuro-inflammatory disorders, multiple sclerosis and other autoimmune diseases as well as for the treatment of other cancers.

Location

91 Bolivar Drive
Berkeley
California
94710
United States of America

Contact

Phone: 510.647.4000
Fax: 510.548.8014
Email: info@plexxikon.com


News Articles [1 Associated News Articles listed on BioPortfolio]

Escient Pharmaceuticals Announces Appointment of K. Peter Hirth to Board of Directors

--Co-founder, former CEO of Plexxikon brings proven track record building platform-based companies and delivering novel medicines for patients-- Escient Pharmaceuticals, Inc., a biotechnology compan...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

This open-label single arm study will assess the efficacy, safety and tolerability of RO5185426 in previously treated patients with metastatic melanoma. Patients will receive oral RO518542...

Companies [2 Associated Companies listed on BioPortfolio]

Plexxikon, Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, ...

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, ...

More Information about "Plexxikon Inc." on BioPortfolio

We have published hundreds of Plexxikon Inc. news stories on BioPortfolio along with dozens of Plexxikon Inc. Clinical Trials and PubMed Articles about Plexxikon Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Plexxikon Inc. Companies in our database. You can also find out about relevant Plexxikon Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....


Corporate Database Quicklinks



Searches Linking to this Company Record